Education
About Us
Working with TipRanks
Follow Us
Pharmaust Limited (AU:NUZ)
ASX:NUZ
NUZ Stock Chart & Stats
AU$0.08
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.08
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.08 - AU$0.18
Previous CloseN/A
Volume246.69K
Average Volume (3M)1.10M
Market Cap
AU$66.35M
Enterprise ValueAU$74.59M
Total Cash (Recent Filing)N/A
Total Debt (Recent Filing)N/A
Price to Earnings (P/E)―
Beta1.02
Next Earnings
Feb 26, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.02
Shares Outstanding829,435,600
10 Day Avg. Volume1,596,000
30 Day Avg. Volume1,096,098
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusModerate Buy
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Pharmaust Limited News
NUZ FAQ
What was Pharmaust Limited’s price range in the past 12 months?
Pharmaust Limited lowest share price was AU$0.08 and its highest was AU$0.18 in the past 12 months.
What is Pharmaust Limited’s market cap?
Pharmaust Limited’s market cap is AU$66.35M.
When is Pharmaust Limited’s upcoming earnings report date?
Pharmaust Limited’s upcoming earnings report date is Feb 26, 2026 which is in 47 days.
How were Pharmaust Limited’s earnings last quarter?
Pharmaust Limited released its earnings results on Aug 25, 2025. The company reported -AU$0.019 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.019.
Is Pharmaust Limited overvalued?
According to Wall Street analysts Pharmaust Limited’s price is currently Overvalued.
Does Pharmaust Limited pay dividends?
Pharmaust Limited does not currently pay dividends.
What is Pharmaust Limited’s EPS estimate?
Pharmaust Limited’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Pharmaust Limited have?
Pharmaust Limited has 829,435,600 shares outstanding.
What happened to Pharmaust Limited’s price movement after its last earnings report?
Pharmaust Limited reported an EPS of -AU$0.019 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went up 3.401%.
Which hedge fund is a major shareholder of Pharmaust Limited?
Currently, no hedge funds are holding shares in AU:NUZ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Pharmaust Limited Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
― (―)
― (―)
Blogger Sentiment
Bullish
AU:NUZ Sentiment 93%
Sector Average ―
Sector Average ―
Insider Transactions
Bought Shares
Worth AU$130.0K over
the Last 3 Months
the Last 3 Months
News Sentiment
Neutral
Bullish news 50%
Bearish news 50%
Bearish news 50%
Technicals
SMA
―
20 days / 200 days
Momentum
-49.63%
12-Months-Change
Fundamentals
Return on Equity
-247.98%
Trailing 12-Months
Asset Growth
-64.90%
Trailing 12-Months
Company Description
Pharmaust Limited
PharmAust Ltd operates as a drug discovery and development company in Australia, Switzerland, and internationally. It develops drug discovery intellectual property for the treatment of various cancers in humans and animals. The company offers Monepantel and Albendazole, which are in Phase II clinical trials for the treatment of cancer. It also provides medicinal and synthetic chemistry services on a contract basis to the drug discovery and pharmaceutical industries.
Technical Analysis
Living Cell Technologies
―
Alterity Therapeutics
―
Prescient Therapeutics Limited
―
Recce Pharmaceuticals Ltd.
―
Arovella Therapeutics Limited
―